Next Article in Journal
Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds
Next Article in Special Issue
State of Art of Cancer Pharmacogenomics in Latin American Populations
Previous Article in Journal
The Balloon-Based Manometry Evaluation of Swallowing in Patients with Amyotrophic Lateral Sclerosis
Previous Article in Special Issue
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(4), 669; doi:10.3390/ijms18040669

OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings

1
Laboratory of Pharmacology, Clinical Pharmacy and Quality Control of Drugs, Pôle Technologie- Santé (PTS), Faculty of Pharmacy, Saint-Joseph University, Beirut 1107 2180, Lebanon
2
Department of Public Health, Faculty of Medicine, Saint-Joseph University, Beirut 1107 2180, Lebanon
3
Department of Prosthodontics, Faculty of Dental Medicine, Saint-Joseph University, Beirut 1107 2180, Lebanon
4
University of Auvergne, CROC-EA4847, Centre de Recherche en Odontologie Clinique, BP 10448, Clermont-Ferrand F-63000, France
5
Department of Hemato-Oncology, Hôtel-Dieu de France Hospital, Faculty of Medicine, Saint-Joseph University, Beirut 1107 2180, Lebanon
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editors: Sabrina Angelini, Gloria Ravegnini and Irmgard Tegeder
Received: 29 December 2016 / Revised: 9 March 2017 / Accepted: 14 March 2017 / Published: 27 March 2017
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine 2016)
View Full-Text   |   Download PDF [523 KB, uploaded 27 March 2017]   |  

Abstract

Despite increased attention on assessment and management, pain remains the most persistent symptom in patients with cancer, in particular in end-of-life settings, with detrimental impact on their quality-of-life (QOL). We conducted this study to evaluate the added value of determining some genetic and non-genetic factors to optimize cancer pain treatment. Eighty-nine patients were included in the study for the evaluation of palliative cancer pain management. The regression analysis showed that age, OPRM1 single nucleotide polymorphism (SNP), as well as the duration of morphine treatment were significantly associated with morphine doses at 24 h (given by infusion pump; p = 0.043, 0.029, and <0.001, respectively). The mean doses of morphine decreased with age but increased with the duration of morphine treatment. In addition, patients with AG genotype c.118A>G OPRM1 needed a higher dose of morphine than AA patients. Moreover, metastases, OPRM1 SNP, age, and gender were significantly associated with the QOL in our population. In particular, AA patients for OPRM1 SNP had significantly lower cognitive function than AG patients, a result not previously reported in the literature. These findings could help increase the effectiveness of morphine treatment and enhance the QOL of patients in regards to personalized medicine. View Full-Text
Keywords: morphine; polymorphism; OPRM1; ABCB1; COMT; pain; pharmacogenetics; cancer; quality-of-life morphine; polymorphism; OPRM1; ABCB1; COMT; pain; pharmacogenetics; cancer; quality-of-life
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hajj, A.; Halepian, L.; Osta, N.E.; Chahine, G.; Kattan, J.; Rabbaa Khabbaz, L. OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings. Int. J. Mol. Sci. 2017, 18, 669.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top